Demystifying Sage Therapeutics: Insights From 5 Analyst Reviews
Demystifying Sage Therapeutics: Insights From 5 Analyst Reviews
揭開Sage療法的神祕面紗：來自5條分析師評論的見解
During the last three months, 5 analysts shared their evaluations of Sage Therapeutics (NASDAQ:SAGE), revealing diverse outlooks from bullish to bearish.
在過去的三個月中，5位分析師分享了他們對Sage Therapeutics（納斯達克股票代碼：SAGE）的評估，揭示了從看漲到看跌的不同前景。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
下表總結了他們最近的評估，說明了過去30天不斷變化的情緒，並將其與前幾個月進行了比較。
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $26.2, with a high estimate of $29.00 and a low estimate of $22.00. Surpassing the previous average price target of $22.50, the current average has increased by 16.44%.
分析師對12個月目標股價的評估提供了更多見解，顯示平均目標價爲26.2美元，最高估計爲29.00美元，低估值爲22.00美元。超過了之前的平均目標價22.50美元，目前的平均價格上漲了16.44％。
Interpreting Analyst Ratings: A Closer Look
解讀分析師評級：仔細觀察
The standing of Sage Therapeutics among financial experts is revealed through an in-depth...
通過對分析師近期行爲的深入探...
登入免費觀看全文
登入/註冊